XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($)
Series A
Preferred Stock
Common Shares
Common Stock
Share Subscription Receivable
Additional Paid-in-Capital
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Total Mawson Stockholders’ Equity
Non-controlling interest
Total
Balance at Dec. 31, 2019 $ 9,093,549 $ (217,003) $ (1,447,092) $ 7,429,454 $ 7,429,454
Balance (in Shares) at Dec. 31, 2019   6,578,672                
Issuance of common stock, net of offering costs $ 105,019 1,633,489 1,738,508 1,738,508
Issuance of common stock, net of offering costs (in Shares)   268,793                
Comprehensive gain / (loss) (91,602) (2,583,351) (2,674,954) (2,674,954)
Balance at Jun. 30, 2020 $ 9,198,568 1,633,489 (308,605) (4,030,443) 6,493,009 6,493,009
Balance (in Shares) at Jun. 30, 2020 6,847,465              
Balance at Mar. 31, 2020 $ 9,198,568   (1,185,739) (1,976,585) 6,036,244 6,036,244
Balance (in Shares) at Mar. 31, 2020 6,578,672                
Issuance of common stock, net of offering costs 1,633,489 1,633,489 1,633,489
Issuance of common stock, net of offering costs (in Shares)   268,793              
Comprehensive gain / (loss) 877,134 (2,053,858) (1,176,724) (1,176,724)
Balance at Jun. 30, 2020 $ 9,198,568 1,633,489 (308,605) (4,030,443) 6,493,009 6,493,009
Balance (in Shares) at Jun. 30, 2020 6,847,465              
Balance at Dec. 31, 2020     (16,690) 15,298,926 (1,341,826) (6,348,465) 7,591,945 (27,066) 7,564,879
Balance (in Shares) at Dec. 31, 2020 7,539,275              
Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio     $ 428,271         428,271   428,271
Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio (in Shares) 178 (7,539,275) 428,270,616              
Acquisition of Wize Pharma Inc.     $ 33,053   (5,436,541) (5,403,488) (5,403,488)
Acquisition of Wize Pharma Inc. (in Shares)   33,052,951              
Issuance of Common stock of Mawson Infrastructure Group, Inc., in a PIPE transaction upon the consummation of the Business Combination     $ 25,000   2,975,000 3,000,000 3,000,000
Issuance of Common stock of Mawson Infrastructure Group, Inc., in a PIPE transaction upon the consummation of the Business Combination (in Shares)   25,000,000              
Issuance of 28,012,364 mandatorily convertible notes by Cosmos Capital, net of $1,268,093 of offering costs     20,441,761 20,441,761 20,441,761
Issuance of 28,012,364 mandatorily convertible notes by Cosmos Capital, net of $1,268,093 of offering costs (in Shares)                  
Issuance of 8,710,982 warrants over Common Stock of Mawson Infrastructure Group, Inc., at the Common Stock price of $0.79       6,881,676 6,881,676 6,881,676
Issuance of 8,710,982 warrants over Common Stock of Mawson Infrastructure Group, Inc., at the Common Stock price of $0.79 (in Shares)                  
Exercise of 115,902 warrants for Mawson Infrastructure Group, Inc. Common Stock     $ 116         116   116
Exercise of 115,902 warrants for Mawson Infrastructure Group, Inc. Common Stock (in Shares)     115,902              
Fair value of IPR&D acquired, net of Business Combination transaction costs     24,765,831 24,765,831 24,765,831
Fair value of IPR&D acquired, net of Business Combination transaction costs (in Shares)                  
Issuance of RSUs and stock options     10,270,803 10,270,803 10,270,803
Issuance of RSUs and stock options (in Shares)                  
Fair value adjustment of LO2A intellectual property revenue sharing obligation     5,440,863 5,440,863 5,440,863
Fair value adjustment of LO2A intellectual property revenue sharing obligation (in Shares)                  
Issuance of common stock (@A$8.75)     $ 13,173 42,502 55,675 55,675
Issuance of common stock (@A$8.75) (in Shares)   2,000              
Share based payment (@A$8.75)     $ 22,582   22,582 22,582
Share based payment (@A$8.75) (in Shares)   3,429              
Share based payments W Capital     $ 5,535,900   5,535,900 5,535,900
Share based payments W Capital (in Shares)   8,250,000              
Comprehensive gain / (loss)         (4,738,946) (44,759,993) (49,498,939) (65,802) (49,564,741)
Balance at Jun. 30, 2021 $ 0 $ 6,058,095 (16,690) 80,638,319 (6,038,270) (51,108,458) 29,532,996 (92,868) 29,440,128
Balance (in Shares) at Jun. 30, 2021 178   494,694,898              
Balance at Mar. 31, 2021 $ 0 $ 486,440 (16,690) 80,638,319 (5,957,154) (44,911,673) 30,239,242 16,069 30,255,311
Balance (in Shares) at Mar. 31, 2021 178   486,439,469              
Issuance of common stock (@A$8.75) $ 13,173 42,502 55,675 55,675
Issuance of common stock (@A$8.75) (in Shares)     2,000              
Share based payment (@A$8.75) $ 22,582 22,582 22,582
Share based payment (@A$8.75) (in Shares)     3,429              
Share based payments W Capital $ 5,535,900 5,535,900 5,535,900
Share based payments W Capital (in Shares)     8,250,000              
Comprehensive gain / (loss) (123,618) (6,196,785) (6,320,403) (108,937) (6,429,340)
Balance at Jun. 30, 2021 $ 0 $ 6,058,095 $ (16,690) $ 80,638,319 $ (6,038,270) $ (51,108,458) $ 29,532,996 $ (92,868) $ 29,440,128
Balance (in Shares) at Jun. 30, 2021 178   494,694,898